ROANOKE, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated earnings of $538,412, or $0.05 per share, for the third quarter ended June 30, 2025, compared to $156,692, or $0.02 per share, for the fiscal quarter ended June 30, 2024. The increase during the quarter was largely the result of higher earnings from the Company’s investment in the Mountain Valley Pipeline, LLC (“MVP”).
EAST HANOVER, N.J., Aug. 11, 2025 /PRNewswire/ -- FGI Industries Ltd. (Nasdaq: FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and...
Rebranding Initiative, including Name Change to RideNow Group, Inc., Corporate Headquarters Relocation Back to Phoenix, AZ Area, and Ticker Symbol Change
Amends, Reprices and Extends...
- Q2 Total Revenue up 10% YoY to $102.9 Million - - Q2 Net Income Increases to $8.2 Million or $0.19 Earnings per Share – - Q2 Operating Cash Flow of $11.4 Million - - Q2 Adjusted EBITDA increases to $3.4 Million -
ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.
Company revenues grew by approximately 32%, reaching about $37 millionGross profit increased by approximately 32%, reaching $26.5 millionNet profit rose by approximately 46%, reaching...
LOS ANGELES, Aug. 10, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2025.
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.
SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.